IQVIA (NYSE:IQV) Price Target Lowered to $232.00 at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its price objective decreased by JPMorgan Chase & Co. from $240.00 to $232.00 in a report published on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

A number of other equities analysts have also issued reports on IQV. Bank of America cut their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Deutsche Bank Aktiengesellschaft reduced their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group dropped their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, Barclays cut their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Price Performance

Shares of NYSE IQV opened at $193.27 on Tuesday. The company’s 50-day moving average price is $200.15 and its 200 day moving average price is $217.43. The stock has a market cap of $35.08 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 2.25 and a beta of 1.48. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts forecast that IQVIA will post 10.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new position in IQVIA in the 4th quarter worth $336,041,000. Raymond James Financial Inc. bought a new stake in IQVIA in the 4th quarter valued at $236,120,000. American Century Companies Inc. lifted its holdings in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. increased its holdings in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.